文献速递真菌感染

分子靶向治疗时代新诊断急性髓系白血病患者中 mold 活性三唑类作为初级抗真菌预防的比较

Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies.
PubMed 文献 · Clin Infect Dis · 2022-01-01

该研究评估了277例接受强化或含维奈克拉低强度诱导化疗的新诊断急性髓系白血病患者中,泊沙康唑、伏立康唑或艾沙康唑作为初级抗真菌预防时突破性侵袭性真菌感染的发生率和特征。突破性侵袭性真菌感染发生率为4%,三种唑类间无显著差异(P=0.55),且中性粒细胞恢复和完全缓解与突破性感染风险相关。

要点

  • 突破性侵袭性真菌感染总发生率为4%,泊沙康唑2.9%、伏立康唑4.8%、艾沙康唑5.7%(P=0.55)。
  • 既往棘白菌素暴露和化疗强度未影响突破性侵袭性真菌感染率。
  • 突破性感染者中性粒细胞恢复>1000 cells/µL的比例更低(64% vs 90%,P=0.021)。

核心结论

  • 在接受任何一种 mold 活性三唑类作为初级预防的新诊断急性髓系白血病诱导化疗患者中,突破性侵袭性真菌感染率低。
  • 中性粒细胞恢复和完全缓解的实现对突破性侵袭性真菌感染风险很重要。

研究设计与样本

  • 研究纳入277例接受强化或含维奈克拉低强度诱导化疗的新诊断急性髓系白血病成人患者。
  • 患者接受泊沙康唑、伏立康唑或艾沙康唑作为初级预防超过5天。
  • 允许在唑类预防开始前使用棘白菌素,但不允许同时使用。
  • 突破性侵袭性真菌感染定义为持续唑类暴露超过5天后或停药14天内发生的侵袭性真菌感染(改良EORTC/MSG标准)。

主要发现

  • 确诊或临床诊断的突破性侵袭性真菌感染见于11例患者(4%)。
  • 突破性侵袭性真菌感染发生率:泊沙康唑2.9%,伏立康唑4.8%,艾沙康唑5.7%(P=0.55)。
  • 161例患者(58%)在唑类预防开始前接受了棘白菌素预防。
  • 棘白菌素暴露和化疗强度均未影响突破性侵袭性真菌感染率。
  • 突破性侵袭性真菌感染患者中性粒细胞绝对计数恢复>1000 cells/µL的比例为64% vs 90%(P=0.021),完全缓解率为18% vs 66%(P=0.002)。

关键数值与推荐

  • 突破性侵袭性真菌感染定义:持续唑类暴露超过5天后或停药14天内发生的侵袭性真菌感染(改良EORTC/MSG标准)。
  • 初级预防用药:泊沙康唑、伏立康唑或艾沙康唑超过5天。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Multiple factors influence the choice of primary antifungal prophylaxis (PAP) in patients with acute myeloid leukemia (AML) undergoing remission induction chemotherapy (RIC) given the recent incorporation of targeted leukemia therapies into these regimens. METHODS: We evaluated the incidence and characteristics of breakthrough invasive fungal infections (bIFI) in 277 adult patients with newly diagnosed AML undergoing RIC with high-intensity, or low-intensity venetoclax-containing therapy. Patients receiving posaconazole (PCZ), voriconazole (VCZ), or isavuconazole (ISA) for > 5 days as PAP during RIC were included. Echinocandin use prior to, but not concomitantly with, the PAP azole was allowed. IFI (modified EORTC/MSG criteria) occurring after > 5 days of continuous azole exposure or within 14 days of discontinuation were considered bIFI. RESULTS: Proven or probable bIFI were observed in 11 patients (4%). The incidence of bIFI was 2.9% for PCZ, 4.8% for VCZ, and 5.7% for ISA (P = .55). In total, 161 patients (58%) received echinocandin prophylaxis prior to azole initiation. Neither echinocandin exposure nor chemotherapy intensity impacted bIFI rate. Patients with bIFI had a lower rate of absolute neutrophil count recovery > 1000 cells/µL (64% vs 90%, P = .021) or complete remission (CR; 18% vs 66%, P = .002) after RIC. Thirty-eight patients (14%) discontinued PAP due to toxicity, most often hepatotoxicity. Discontinuation due to hepatotoxicity was similar among azoles (PCZ: 13%; VCZ: 15%; ISA: 13%). CONCLUSIONS: The rate of bIFI is low during RIC in patients with newly diagnosed AML receiving any of the mold-active triazoles as PAP. Neutrophil recovery and achievement of CR are important for bIFI risk.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Rausch CR, DiPippo AJ, Jiang Y, et al. Comparison of Mold Active Triazoles as Primary Antifungal Prophylaxis in Patients With Newly Diagnosed Acute Myeloid Leukemia in the Era of Molecularly Targeted Therapies. Clin Infect Dis. 2022. PMID: 35325094. doi:10.1093/cid/ciac230

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。